Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection

Karlafti, Eleni; Hatzitolios, Apostolos; Karlaftis, Anastasios; Baltatzi, Maria; Κολιάκος, Γεώργιος; Savopoulos, Christos

doi:10.4103/0975-7406.120067

Cited by 13 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, monitoring a central sympathetic outflow and circulating norepinephrine levels in hypertensive patients highlighted the role of the SNS as an important therapeutic target. This led to the development of moxonidine, a drug that lowers BP by suppressing SNS activity [ 25 ]. Our current study highlights for the first time that TNFSF14 levels are reduced with antihypertensive therapy.…”

Section: Discussionmentioning

confidence: 99%

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α

Magno

Herat

Kiuchi

et al. 2020

JCM

View full text Add to dashboard Cite

Studying the role of circulatory factors in the pathogenesis of diseases has been key to the development of effective therapies. We sought to examine the effect of antihypertensive therapies on numerous circulatory factors including short chain fatty acids and growth factors in a human cohort. A subset of participants from an earlier study was characterized by their hypertensive and/or treatment status and separated into three groups: (i) normotensives; (ii) untreated hypertensive and (iii) treated hypertensive subjects. Circulating levels of short chain fatty acids, FGF21 and TNF superfamily members were measured as part of this study. Both F2-isoprostane and circulating lipid levels were reanalysed as part of this current study. We found that antihypertensive treatment increased butyrate levels and decreased acetate levels to levels similar to normotensives. We also found that antihypertensive treatments reduced levels of circulating FGF21, TNFSF14 and TNF-α. In conclusion, we identified several circulatory factors that are altered in hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α

Magno

Herat

Kiuchi

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Результатом является ингибирование периферического α-адренергического тонуса и снижение АД из-за снижения сосудистого сопротивления [16]. Многочисленные исследования демонстрируют, что терапия моксонидином обладает органопротективным действием [17].…”

Section: стресс и ссо у пациентов с агunclassified

“…В исследовании E. Karlafti и соавт. установлено, что наибольшее снижение ЧСС наблюдалось у пациентов с ЧСС более 80 уд/мин в покое до начала терапии, а у пациентов с ЧСС менее 70 уд/мин снижения данного показателя не отмечено [20]. Это позволяет модифицировать еще один фактор риска ССО у пациентов с АГ без нежелательных явлений со стороны метаболических нарушений в сравнении с β-адреноблокаторами.…”

Section: стресс и ссо у пациентов с агunclassified

The role of stress and sleep disorders in the development of cardiovascular complications in patients with arterial hypertension: what is important for an internist to know? A review

Ионин

2023

Consilium Medicum

View full text Add to dashboard Cite

This publication discusses the mechanisms underlying the development of arterial hypertension on the background of stress, discusses the current problems of blood pressure control in patients with stress-induced sleep disorders, the clinical features of patients with hypersympathicotonia as the main mechanism for the development of arterial hypertension and blood pressure variability in patients with comorbid pathology, a diagnostic algorithm, as well as presenting current recommendations in the strategy for choosing the optimal antihypertensive therapy with the possibility of personalized choice in various clinical situations.

show abstract

“…на фоне лечения моксонидином происходит повышение индекса чувствительности к инсулину и скорости утилизации глюкозы. Также имеются данные о том, что моксонидин уменьшает ЧСС -клинический маркер гиперсимпатикотонии [40].…”

Section: Optimization Of Pharmacotherapy In Multimorbidity Patientsunclassified

Optimization of Pharmacotherapy Within the Framework of a Patient-oriented Approach in the Treatment of Hypertension in Multimorbidity Patients (Clinical Case and Literature Review)

Остроумова

Alyautdinova

Litvinova

et al. 2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Arterial hypertension (AH) remains one of the main causes of disability and death worldwide, including in Russia. At the same time, the risks of coronary and cerebrovascular events increase in the presence of additional risk factors. The most common modifiable risk factors are metabolic disorders, including pre-diabetes, dyslipidemia, peripheral arterial atherosclerosis, and obesity, which also imposes certain features on the choice of optimal pharmacotherapy. Currently, the terminology of comorbid conditions continues to be discussed depending on their pathogenesis and the presence or absence of dominance of one disease over others, i.e. polymorbidity, comorbidity and multimorbidity. At the same time, “associative polymorbidity” is distinguished with a certain set of diseases that often occur in conjunction with each other with individual susceptibility of the body. One of the most common phenotypes of polymorbidity occurring in all age groups in both sexes is cardiometabolic, which is based on the formation of insulin resistance, sympathetic overactivity and chronic inflammation. This article provides a clinical example of the use of a fixed combination of angiotensin II receptor blocker telmisartan and calcium channel blocker amlodipine with the addition of an I1-imidazoline receptor agonist moxonidine in real clinical practice in a polymorbid cardiometabolic patient with target organ damage (left ventricular hypertrophy and microalbuminuria). High antihypertensive (favorable effect on 24-hour blood pressure, especially in the early morning) and organoprotective effectiveness of this combination, its possibilities in correcting additional risk factors (reduced heart rate, body weight and a positive effect on metabolic parameters), due to a synergistic effect on the central pathogenetic mechanisms of hypertension and obesity – insulin resistance and sympathetic overactivity.

show abstract

Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection

Cited by 13 publications

References 29 publications

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α

The role of stress and sleep disorders in the development of cardiovascular complications in patients with arterial hypertension: what is important for an internist to know? A review

Optimization of Pharmacotherapy Within the Framework of a Patient-oriented Approach in the Treatment of Hypertension in Multimorbidity Patients (Clinical Case and Literature Review)

Contact Info

Product

Resources

About